Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 4
2017 6
2018 7
2019 3
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.
Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, Song J, Li L, Dagenborg VJ, Fretland ÅA, Røsok B, De Rose AM, Ardito F, Edwin B, Panettieri E, Larocca LM, Yamashita S, Conrad C, Aloia TA, Poston GJ, Bjørnbeth BA, Vauthey JN. Brudvik KW, et al. Among authors: conrad c. Ann Surg. 2019 Jan;269(1):120-126. doi: 10.1097/SLA.0000000000002319. Ann Surg. 2019. PMID: 28549012
OBJECTIVE: To determine the impact of RAS mutation status on the traditional clinical score (t-CS) to predict survival after resection of colorectal liver metastases (CLM). ...The m-CS was validated in an international multicenter cohort of 608 patients. RESULTS: A total o …
OBJECTIVE: To determine the impact of RAS mutation status on the traditional clinical score (t-CS) to predict survival after resectio …
RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
Denbo JW, Yamashita S, Passot G, Egger M, Chun YS, Kopetz SE, Maru D, Brudvik KW, Wei SH, Conrad C, Vauthey JN, Aloia TA. Denbo JW, et al. Among authors: conrad c. J Gastrointest Surg. 2017 Jan;21(1):68-77. doi: 10.1007/s11605-016-3189-9. Epub 2016 Jun 22. J Gastrointest Surg. 2017. PMID: 27334313
RESULTS: Ninety-eight patients underwent RH, of whom 34 (35 %) harbored a RAS mutation. Wild-type (WT) and mutant RAS groups had similar clinicopathologic characteristics. ...CONCLUSION: Patients with recurrent CLM that harbor RAS mutations have worse RFS and …
RESULTS: Ninety-eight patients underwent RH, of whom 34 (35 %) harbored a RAS mutation. Wild-type (WT) and mutant RAS groups h …
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN. Chun YS, et al. Among authors: conrad c. Ann Surg. 2019 May;269(5):917-923. doi: 10.1097/SLA.0000000000002450. Ann Surg. 2019. PMID: 28767562 Free PMC article.
The negative prognostic effects of RAS and TP53 mutations were limited to tumors harboring mutations in both genes. CONCLUSIONS: Concomitant RAS and TP53 mutations are associated with decreased survival after CLM resection. ...
The negative prognostic effects of RAS and TP53 mutations were limited to tumors harboring mutations in both genes. CONCLUSIONS: Conc …
RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C. Okuno M, et al. Among authors: conrad c. Ann Surg Oncol. 2018 Aug;25(8):2457-2466. doi: 10.1245/s10434-018-6517-3. Epub 2018 May 21. Ann Surg Oncol. 2018. PMID: 29786130
RAS mutation was associated with poor post-recurrence survival in both patients who received local therapy and those who received chemotherapy only. CONCLUSIONS: RAS mutation predicts recurrence not amenable to any local therapy and shorter post-recurrence survival
RAS mutation was associated with poor post-recurrence survival in both patients who received local therapy and those who received che
Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group. Passot G, et al. Among authors: conrad c. Ann Surg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017 Oct 25. Ann Surg Oncol. 2018. PMID: 29071660
BACKGROUND: RAS mutation status is an important prognostic factor after resection of liver metastases (LiM) from colorectal cancer (CRC). The prognostic significance of RAS after resection of lung (LuM) and peritoneal (PM) metastases from CRC is unknown. ...
BACKGROUND: RAS mutation status is an important prognostic factor after resection of liver metastases (LiM) from colorectal cancer (C …
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. Brudvik KW, et al. Among authors: conrad c. Ann Surg Oncol. 2016 Aug;23(8):2635-43. doi: 10.1245/s10434-016-5187-2. Epub 2016 Mar 25. Ann Surg Oncol. 2016. PMID: 27016292 Free PMC article.
RESULTS: The study included 633 patients, of whom 229 (36.2 %) had mutant RAS. The positive margin rate was 11.4 % (26/229) for mutant RAS and 5.4 % (22/404) for wild-type RAS (p = 0.007). ...Tumors with RAS mutation should prompt careful efforts to ac …
RESULTS: The study included 633 patients, of whom 229 (36.2 %) had mutant RAS. The positive margin rate was 11.4 % (26/229) for mutan …
APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S, Chun YS, Kopetz SE, Maru D, Conrad C, Aloia TA, Vauthey JN. Yamashita S, et al. Among authors: conrad c. Ann Surg. 2020 Dec;272(6):1080-1085. doi: 10.1097/SLA.0000000000002245. Ann Surg. 2020. PMID: 28379870
Independent predictors of major pathologic response were bevacizumab use (odds ratio [OR] 2.22; P = 0.001), tumor size <3 cm (OR 1.97; P = 0.004), wild-type RAS (OR 2.00; P = 0.003), and absence of double mutation (OR 2.91; P = 0.002). Independent predictors of worse OS …
Independent predictors of major pathologic response were bevacizumab use (odds ratio [OR] 2.22; P = 0.001), tumor size <3 cm (OR 1.97; P …
Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Passot G, et al. Among authors: conrad c. Surgery. 2017 Feb;161(2):332-340. doi: 10.1016/j.surg.2016.07.032. Epub 2016 Aug 31. Surgery. 2017. PMID: 27592215

BACKGROUND: RAS mutations are associated with limited overall survival after resection of colorectal liver metastases. ...At median follow-up of 38 months, median overall survival was 72.6 months for wild-type RAS and 50.9 months for mutated RAS (P < .001)

BACKGROUND: RAS mutations are associated with limited overall survival after resection of colorectal liver metastases. ...At median f …
Comprehensive Complication Index Predicts Cancer-specific Survival After Resection of Colorectal Metastases Independent of RAS Mutational Status.
Yamashita S, Sheth RA, Niekamp AS, Aloia TA, Chun YS, Lee JE, Vauthey JN, Conrad C. Yamashita S, et al. Among authors: conrad c. Ann Surg. 2017 Dec;266(6):1045-1054. doi: 10.1097/SLA.0000000000002018. Ann Surg. 2017. PMID: 27735824
OBJECTIVE: To investigate prognostic impact of postoperative complications for colorectal liver metastases (CLM) in the era of RAS mutation analysis. BACKGROUND: Postoperative complications have been associated with cancer-specific outcomes in multiple malignancies. METHOD …
OBJECTIVE: To investigate prognostic impact of postoperative complications for colorectal liver metastases (CLM) in the era of RAS mu …
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page